Medtronic (NYSE:MDT) said today that it enrolled the first patient in a study to assess the use of the company’s SynchroMed II intrathecal drug delivery system as an alternative to oral opioids.
The 100-patient Embrace TDD study is slated to follow patients who have weaned off all oral opioids, in the hopes of proving the efficacy and tolerability of the SynchroMed II pump as a viable alternative for people with chronic intractable non-malignant primary back pain.
Get the full story at our sister site, Drug Delivery Business News.
The post Medtronic kicks off study for pain pump appeared first on MassDevice.
from MassDevice http://bit.ly/2T0xBu2
Cap comentari:
Publica un comentari a l'entrada